An interventional study of Extracorporal therapy in Kidney Diseases, Kidney Transplant Infection and Kidney Transplant; Complications, sponsored by ExThera Medical Europe BV. Withdrawn at 1 site in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by ExThera Medical Europe BV · Not applicable, Interventional, and Treatment
Reduction of BK Viremia by treating kidney transplant patients.
a clinical investigation plan (CIP) for the "Reduction of BK viremia in kidney transplant patients using the Seraph 100 Microbind® Affinity (Seraph 100) Blood Filter" clinical study, where BK is an abbreviation of the name of the first patient whom the virus was isolated from in 1971. This clinical study is intended to evaluate the reduction of BK viremia by treating kidney transplant patients with the Seraph 100 Microbind® Affinity Blood Filter from ExThera Medical. This clinical study is sponsored by ExThera Medical Corporation.
This clinical study will be conducted in accordance with this CIP. All parties involved in the conduct of the clinical study will be qualified by education, training, or experience to perform their tasks and this training will be documented appropriately.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
Browse Kidney Diseases studies →ExThera Medical Europe BV is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treatment with Microbind® Affinity Blood Filter
Device: Extracorporal therapy
Antibiotics
Extracorporal therapy
Change in log 10 viral load
Time-weighted change from baseline in log10 viral load within five days after first treatment.
Time frame: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
Number of participants with leukopenia
Number of participants with leukopenia
Time frame: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
Number of participants with increase in serum creatinine
Number of participants with increase in serum creatinine between the treatment days
Time frame: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
Number of participants with inoperative hypotension
Number of participants with inoperative hypotension per treatment period
Time frame: At 0 and the following 3 treatments within five days after beginning with the first treatment.
Number of participants with decreasing haemoglobin measurements
Number of participants with decreasing haemoglobin measurements per treatment period
Time frame: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
N (%) of patients with treatment emergent adverse events
N (%) of patients with treatment emergent adverse events
Time frame: 2 months
Laboratory data
Laboratory data (Blood test, Hematology, chemistry and coagulation)
Time frame: 2 months
Vital signs score
Vital signs score
Time frame: 2 months
Physical examination score
Physical examination score
Time frame: 2 months
Plan to share: Yes
Supporting information: Csr
No publications or documents are linked to this record.
This study is withdrawn, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ExThera Medical Europe BV